WILDTYPE IGG ANTIBODY
- Any unmodified IgG
- Any isotype
- No prior engineering
- No glycan removal
Product
Highlights platform flexibility – wildctype mAb input, modular LP kit, tunable DAR. Appeals to BD and scientists alike.
Current platform limitations
TRIDENT overcomes all three constraints – no antibody engineering, no glycan clipping, no disulfide shuffling risk, flexible DAR from a single two-step protocol.
TRIDENT is a two-step, enzyme-mediated site specific conjugation platform. Start with any unmodified IgG antibody – no prior engineering required
Trident enzyme selectively transfers a click handle bearing linker to a defined set a defined site on the Fc region of the native antibody.
User attaches payload of choice via bioorthogonal click chemistry to the installed handle, completing the ADC in a single, controlled reaction.
TRIDENT is the first site-specific conjugation platform to combine native
Fc preservation, zero antibody engineering, and flexible DAR in a single off-the-shelf kit format.
Works on any wildtype IgG – no mutagenesis, no sequence modification, no cell line redevelopment. Start conjugating immediately.
Unlike glycan-clipping platforms, TRIDENT leaves the Fc N-glycan undisturbed. Native effector function, half-life, and FcRn binding are preserved.
Stoichiometry-controlled DAR selection from the same platform and kit. No platform switching when payload potency requirements change.
Celltheon’s linker-payloads incorporate a proprietary solubility-enhancing moiety, enabling high-DAR ADCs without aggregation penalties.
Enzyme and linker-payload components available as qualified GMP and GLP kits. No custom synthesis, no lead time for reagents.
TRIDENT is Celltheon’s proprietary platform offered directly to clients. No third-party licensing burden on your ADC program.
Subtitle
Select your target drug-to-antibody ratio based on payload potency and indication – determined by linker structure, from a single TRIDENT kit format.
How to Access TRIDENT
Proof Points & Evidence



Quick answers about timelines, quality, and how to work with Celltheon.
Celltheon builds biotech technology platforms and delivers end-to-end solutions that bridge early drug development and manufacturing.
We support biotech and biopharma teams from discovery through preclinical development and manufacturing readiness.
Our offering spans DNA, protein production, engineering, developability, assays, stable cell lines, conjugation, and process development.
Both. Programs can use an integrated workflow or select the individual services and technologies they need.
Yes. Choose platform transfer to your team or a service model executed by Celltheon scientists.
We begin with your goals, molecule, timeline, and deliverables, then provide a clear technical plan and project scope.
We share relevant case studies, quality documentation, platform data, and a project-specific package aligned with your requirements.